The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause

Table 4

Cardiovascular events (venous thromboembolism, stroke, and coronary artery disease) reported in SMART trials (data presented as incidence per 1000 women/year, CI 95%) [53].

Dose	Venous thromboembolism	Stroke	Coronary artery disease
BZA 20 mg/CE 0.45 mg	0.3 (0.0–2.0)	0.4 (0.0–2.4)	2.6 (0.0–5.6)
BZA 20 mg/CE 0.625 mg	0 (0.0–1.5)	0.2 (0.0–1.9)	1.4 (0.0–3.9)
BZA/CE all doses	0.7 (0.0–1.5)	0.44 (0.0–1.1)	2.4 (1.0–3.7)
Placebo	0.6 (0.0–2.9)	0.0 (0.0–1.7)	2.0 (0.0–5.2)